Venetoclax-Based Regimen Shows Promising Survival in Ph- ALL
A phase 2 study found that a venetoclax-based regimen significantly improved survival rates in adolescents and adults with newly diagnosed Philadelphia chromosome-negative acute lymphoblastic leukemia compared to historical chemotherapy cohorts. The study reported high rates of measurable residual disease negativity and overall survival, although it noted an increased incidence of certain adverse events. Researchers emphasized the regimen's potential benefits while acknowledging its associated treatment-related toxicity.
- ▪The venetoclax-based regimen achieved a 78.5% estimated 2-year overall survival rate.
- ▪Among 160 patients assessed, 91% achieved complete remission after induction chemotherapy.
- ▪The regimen was associated with a higher rate of grade ≥ 3 intestinal obstruction compared to historical cohorts.
Medscape files mainly under health. We currently carry 231 of its stories.
Story provenance
Source · retrieval · rights · ranking — open for full record
inspect →
Story provenance
Attribution is not the same as permission. This drawer separates discovery metadata, excerpts, WeSearch-generated summaries, reuse status, and whether the publisher receives the visit. Nothing here claims a legal grant the publisher has not made.
Record
| Original publisher | Medscape |
| Canonical URL | https://www.medscape.com/viewarticle/venetoclax-based-regimen-shows-promising-survival-ph-all-2026a1000igq?src=rss |
| Publication time | Wed, 3 Jun 2026 05:32:17 EDT |
| Retrieval time | 2026-06-03T09:42:00.459Z |
| Last seen | 2026-06-03T09:42:00.459Z |
| Headline source | Publisher (no WeSearch rewrite) |
| Excerpt source | publisher body |
| Excerpt method | First ~120 words (~800 chars) of extracted publisher body, fair-use limited. |
| Summary | WeSearch · cerebras-chat (WeSearch summarizer) |
| Summary source text | contentText |
| Citation coverage | Summary is a WeSearch-generated derivative; primary citation is the original publisher URL. |
| Cluster | geykPkUqzquK |
| Cluster logic | Grouped by semantic title/content similarity across sources within a rolling window. Same-publisher template collisions are excluded from coverage comparison. |
| Ranking reason | Story pages are not engagement-ranked. Hub feeds use recency, with optional source-diversified chronological ordering (cap consecutive stories per source). No personalized ranking. |
| Publisher visit | Yes — open original |
| Substitutes article? | No — link-out required for full text |
Rights status (four layers)
WeSearch handling by dimension
| Indexing | May the item be indexed (stored, ranked, made findable)? | Allowed |
| Snippet | May a short excerpt of the publisher's text be shown? | Allowed |
| AI summary | May WeSearch generate its own short summary of the article? | Limited |
| Retrieval / RAG | May the content be exposed for third-party retrieval-augmented generation? | Not asserted |
| Model training | May the content be used to train AI models? | Not asserted |
| Commercial reuse | May the content be reused commercially? | Not permitted |
Basis: Derived from the published RSS/Atom feed. Contact: [email protected]. Reviewed: 2026-07-24.
Opening excerpt (first ~120 words) tap to expand
TOPLINE:A venetoclax-based pediatric-inspired regimen achieved high rates of postinduction measurable residual disease negativity and was associated with improved survival compared with a propensity score-matched historical chemotherapy cohort among adolescents and adults with newly diagnosed Philadelphia chromosome-negative (Ph-) acute lymphoblastic leukemia (ALL), according to a phase 2 study. The overall incidence of grade ≥ 3 adverse events was similar to that observed in the historical cohort, but the venetoclax-based regimen was associated with a markedly higher rate of grade ≥ 3 intestinal obstruction (18.1% vs 5.6%) as well as treatment-related deaths during induction.METHODOLOGY:Adolescents and adults with Ph- ALL generally have worse survival outcomes than children.
…
Excerpt limited to ~120 words for fair-use compliance. The full article is at Medscape.
Discussion
0 commentsMore from Medscape
